Active Ingredient History

  • Now
Eliprodil is an NMDA antagonist drug candidate which selectively inhibits the NR2B (GLUN2B) subtype NMDA receptor at submicromolar concentrations. Eliprodil failed a Phase III clinical trial for the treatment of acute ischemic stroke in 1996, sponsored by Synthélabo Recherche.   Wikipedia

  • SMILES: OC(CN1CCC(Cc2ccc(F)cc2)CC1)c3ccc(Cl)cc3
  • Mol. Mass: 347.86
  • ALogP: 4.47
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
1-piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)- | (4-chlorophenyl)-4-((4-fluorophenyl)methyl)-1-piperidineethanol | eliprodil | sl 82-0715 | sl 82.0715 | sl-820715


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue